Ysios Capital — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings.
BiotechHealthtechMedical Devices
Pieter ReitsmainJohn Glasspool(Chief Executive Officer)in
Co-investorsSound BioventuresBioGeneration VenturesEICEQT Life SciencesInkefUNIIQ+2 more
Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target.
BiotechHealthtechMedical DevicesNijmegen, NL
Co-investorsBifLightstone VenturesNew Enterprise Associates (NEA)Novartis Venture FundGilde HealthcareOost NL
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.